Business Wire

U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for ...

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) ...
Nasdaq

U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for ...

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) ...